1. Home
  2. PCN vs CDNA Comparison

PCN vs CDNA Comparison

Compare PCN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Strategy Fund

PCN

Pimco Corporate & Income Strategy Fund

HOLD

Current Price

$12.82

Market Cap

846.9M

Sector

Finance

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$19.93

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCN
CDNA
Founded
2001
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
846.9M
1.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PCN
CDNA
Price
$12.82
$19.93
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$26.67
AVG Volume (30 Days)
218.7K
722.8K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
9.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.22
Revenue
N/A
$357,998,000.00
Revenue This Year
N/A
$14.11
Revenue Next Year
N/A
$11.75
P/E Ratio
N/A
$15.75
Revenue Growth
N/A
14.46
52 Week Low
$10.70
$10.96
52 Week High
$14.48
$25.95

Technical Indicators

Market Signals
Indicator
PCN
CDNA
Relative Strength Index (RSI) 60.01 60.33
Support Level $12.66 $18.75
Resistance Level $12.82 $20.61
Average True Range (ATR) 0.08 0.73
MACD 0.03 -0.17
Stochastic Oscillator 94.12 52.07

Price Performance

Historical Comparison
PCN
CDNA

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: